Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 27, Number 6—June 2021
Research

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children

Matt WassermanComments to Author , Ruth Chapman, Rotem Lapidot, Kelly Sutton, Desmond Dillon-Murphy, Shreeya Patel, Erica Chilson, Vincenza Snow, Raymond Farkouh, and Stephen Pelton
Author affiliations: Pfizer Inc., New York, New York, USA (M. Wasserman, E. Chilson, V. Snow, R. Farkouh); Evidera Market Access Ltd, London, UK (R. Chapman, K. Sutton, D. Dillon-Murphy, S. Patel); Boston University School of Medicine, Boston, Massachusetts, USA (R. Lapidot, S. Pelton)

Main Article

Figure 1

Effects of PCVs on invasive pneumococcal disease (IPD) and otitis media among children <5 years of age, United States, 1997–2019 (8,12). A) Cases of IPD. B) Cases of IPD caused by 13-valent PCV serotypes. C) Healthcare visits for otitis media. The United States approved 7-valent PCV in 2000 and 13-valent PCV in 2010. Asterisk (*) indicates that for data on healthcare visits for otitis media, age range is 0–2 years. PCV, pneumococcal conjugate vaccine.

Figure 1. Effects of PCVs on invasive pneumococcal disease (IPD) and otitis media among children <5 years of age, United States, 1997–2019 (8,12). A) Cases of IPD. B) Cases of IPD caused by 13-valent PCV serotypes. C) Healthcare visits for otitis media. The United States approved 7-valent PCV in 2000 and 13-valent PCV in 2010. Asterisk (*) indicates that for data on healthcare visits for otitis media, age range is 0–2 years. PCV, pneumococcal conjugate vaccine.

Main Article

References
  1. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-9):135.PubMed
  2. Douglas  RM, Paton  JC, Duncan  SJ, Hansman  DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis. 1983;148:1317. DOIPubMed
  3. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54:8937.PubMed
  4. Kellner  JD, Vanderkooi  OG, MacDonald  J, Church  DL, Tyrrell  GJ, Scheifele  DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis. 2009;49:20512. DOIPubMed
  5. Black  S, Shinefield  H, Fireman  B, Lewis  E, Ray  P, Hansen  JR, et al.; Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:18795. DOIPubMed
  6. Haber  M, Barskey  A, Baughman  W, Barker  L, Whitney  CG, Shaw  KM, et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine. 2007;25:53908. DOIPubMed
  7. Miller  E, Andrews  NJ, Waight  PA, Slack  MP, George  RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:7608. DOIPubMed
  8. Eskola  J. Polysaccharide-based pneumococcal vaccines in the prevention of acute otitis media. Vaccine. 2000;19(Suppl 1):S7882. DOIPubMed
  9. Strutton  DR, Farkouh  RA, Rubin  JL, McGarry  LJ, Loiacono  PM, Klugman  KP, et al. Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data. BMC Infect Dis. 2012;12:175. DOIPubMed
  10. Centers for Disease Control and Prevention (CDC). National, state, and urban area vaccination coverage among children aged 19-35 months—United States, 2005. MMWR Morb Mortal Wkly Rep. 2006;55:98893.PubMed
  11. Tau  N, Yahav  D, Shepshelovich  D. Postmarketing safety of vaccines approved by the U.S. Food and Drug Administration: a cohort study. Ann Intern Med. 2020;173:4459. DOIPubMed
  12. Centers for Disease Control and Prevention. Active Bacterial Core surveillance: surveillance reports. 2020 [cited 2020 Feb 29]. https://www.cdc.gov/abcs/reports-findings/surv-reports.html
  13. Chapman  R, Sutton  K, Dillon-Murphy  D, Patel  S, Hilton  B, Farkouh  R, et al. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis. Vaccine. 2020;38:713845. DOIPubMed
  14. Moher  D, Liberati  A, Tetzlaff  J, Altman  DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. DOIPubMed
  15. Loo  JD, Conklin  L, Fleming-Dutra  KE, Deloria Knoll  M, Park  DE, Kirk  J, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J. 2014;33(Suppl 2):S14051. DOIPubMed
  16. Tan  TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25:40919. DOIPubMed
  17. Tin Tin Htar  M, van Den Biggelaar  AHJ, Sings  H, Ferreira  G, Moffatt  M, Hall-Murray  C, et al. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review. Expert Rev Vaccines. 2019;18:106989. DOIPubMed
  18. Myint  TTH, Madhava  H, Balmer  P, Christopoulou  D, Attal  S, Menegas  D, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30:12751. DOIPubMed
  19. Aliberti  S, Kaye  KS. The changing microbiologic epidemiology of community-acquired pneumonia. Postgrad Med. 2013;125:3142. DOIPubMed
  20. Arguedas  A, Soley  C, Abdelnour  A. Prevenar experience. Vaccine. 2011;29(Suppl 3):C2634. DOIPubMed
  21. Balsells  E, Guillot  L, Nair  H, Kyaw  MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS One. 2017;12:e0177113. DOIPubMed
  22. United States Census Bureau. Population and housing unit estimates tables. 2020 [cited 2020 Mar 1]. https://www.census.gov/programs-surveys/popest/data/tables.html
  23. Zhou  X, de Luise  C, Gaffney  M, Burt  CW, Scott  DA, Gatto  N, et al. National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States. Int J Pediatr Otorhinolaryngol. 2019;119:96102. DOIPubMed
  24. Simonsen  L, Taylor  RJ, Young-Xu  Y, Haber  M, May  L, Klugman  KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2:e0030910. DOIPubMed
  25. Foote  EM, Singleton  RJ, Holman  RC, Seeman  SM, Steiner  CA, Bartholomew  M, et al. Lower respiratory tract infection hospitalizations among American Indian/Alaska Native children and the general United States child population. Int J Circumpolar Health. 2015;74:29256. DOIPubMed
  26. Grijalva  CG, Griffin  MR, Nuorti  JP, Walter  ND; Centers for Disease Control and Prevention (CDC). Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine—United States, 1997-2006. MMWR Morb Mortal Wkly Rep. 2009;58:14.PubMed
  27. Lessa  FC, Spiller  MT, Soda  E, Weinberger  D, Griffin  MR, Grijalva  CG, et al. Impact of introduction of infant vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) on pneumonia and invasive pneumococcal disease (IPD) hospitalizations in the United States, 2005–2014. Presented at: 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15–19: Melbourne, Victoria, Australia.
  28. Tong  S, Amand  C, Kieffer  A, Kyaw  MH. Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008-2014. BMC Health Serv Res. 2018;18:715. DOIPubMed
  29. Grijalva  CG, Nuorti  JP, Arbogast  PG, Martin  SW, Edwards  KM, Griffin  MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:117986. DOIPubMed
  30. Black  S, Shinefield  H, Baxter  R, Austrian  R, Elvin  L, Hansen  J, et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine. 2006;24(Suppl 2):S279, 80. DOIPubMed
  31. Yildirim  I, Little  BA, Finkelstein  J, Lee  G, Hanage  WP, Shea  K, et al.; T; he Massachusetts Dept. of Public Health. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness. Vaccine. 2017;35:40029. DOIPubMed
  32. Marom  T, Tan  A, Wilkinson  GS, Pierson  KS, Freeman  JL, Chonmaitree  T. Trends in otitis media-related health care use in the United States, 2001-2011. JAMA Pediatr. 2014;168:6875. DOIPubMed
  33. Tong  S, Amand  C, Kieffer  A, Kyaw  MH. Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008-2014. BMC Health Serv Res. 2018;18:318. DOIPubMed
  34. Ray  GT, Pelton  SI, Klugman  KP, Strutton  DR, Moore  MR. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine. 2009;27:648394. DOIPubMed
  35. Pulido  M, Sorvillo  F. Declining invasive pneumococcal disease mortality in the United States, 1990-2005. Vaccine. 2010;28:88992. DOIPubMed
  36. World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age, 2000. 2014 [cited 2020 Mar 1]. https://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en
  37. Shiri  T, Khan  K, Keaney  K, Mukherjee  G, McCarthy  ND, Petrou  S. Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions. Value Health. 2019;22:132944. DOIPubMed
  38. Dagan  R, Ben-Shimol  S, Greenberg  D, Givon-Lavi  N. A prospective, population-based study to determine the incidence and bacteriology of bacterial conjunctivitis in children <2 years following PCV7/PCV13 sequential implementation. Clin Infect Dis. 2020 Mar 4 [Epub ahead of print].
  39. Porat  N, Benisty  R, Givon-Lavi  N, Trefler  R, Dagan  R. The impact of pneumococcal conjugate vaccines on carriage of and disease caused by Streptococcus pneumoniae serotypes 6C and 6D in southern Israel. Vaccine. 2016;34:280612. DOIPubMed
  40. Jansen  KU, Anderson  AS. The role of vaccines in fighting antimicrobial resistance (AMR). Hum Vaccin Immunother. 2018;14:21429. DOIPubMed
  41. Wantuch  PL, Avci  FY. Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them. Hum Vaccin Immunother. 2018;14:23039. DOIPubMed

Main Article

Page created: April 15, 2021
Page updated: April 29, 2021
Page reviewed: April 29, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external